Japan
· Delayed Price · Currency is JPY Takara Bio Statistics
Total Valuation
Takara Bio has a market cap or net worth of JPY 94.29 billion. The enterprise value is 66.19 billion.
| Market Cap | 94.29B |
| Enterprise Value | 66.19B |
Important Dates
The next estimated earnings date is Friday, August 8, 2025.
| Earnings Date | Aug 8, 2025 |
| Ex-Dividend Date | Mar 28, 2025 |
Share Statistics
Takara Bio has 120.42 million shares outstanding.
| Current Share Class | 120.42M |
| Shares Outstanding | 120.42M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | -0.00% |
| Owned by Insiders (%) | 0.48% |
| Owned by Institutions (%) | 10.25% |
| Float | 46.03M |
Valuation Ratios
The trailing PE ratio is 90.57 and the forward PE ratio is 29.12.
| PE Ratio | 90.57 |
| Forward PE | 29.12 |
| PS Ratio | 2.09 |
| PB Ratio | 0.81 |
| P/TBV Ratio | 0.88 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | 16.13 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 9.81, with an EV/FCF ratio of -16.44.
| EV / Earnings | 63.58 |
| EV / Sales | 1.47 |
| EV / EBITDA | 9.81 |
| EV / EBIT | 29.25 |
| EV / FCF | -16.44 |
Financial Position
The company has a current ratio of 8.09, with a Debt / Equity ratio of 0.01.
| Current Ratio | 8.09 |
| Quick Ratio | 6.11 |
| Debt / Equity | 0.01 |
| Debt / EBITDA | 0.16 |
| Debt / FCF | -0.27 |
| Interest Coverage | 113.15 |
Financial Efficiency
Return on equity (ROE) is 0.95% and return on invested capital (ROIC) is 1.23%.
| Return on Equity (ROE) | 0.95% |
| Return on Assets (ROA) | 1.15% |
| Return on Invested Capital (ROIC) | 1.23% |
| Return on Capital Employed (ROCE) | 1.91% |
| Revenue Per Employee | 24.50M |
| Profits Per Employee | 566,376 |
| Employee Count | 1,838 |
| Asset Turnover | 0.37 |
| Inventory Turnover | 1.56 |
Taxes
In the past 12 months, Takara Bio has paid 910.00 million in taxes.
| Income Tax | 910.00M |
| Effective Tax Rate | 45.59% |
Stock Price Statistics
The stock price has decreased by -22.63% in the last 52 weeks. The beta is 0.34, so Takara Bio's price volatility has been lower than the market average.
| Beta (5Y) | 0.34 |
| 52-Week Price Change | -22.63% |
| 50-Day Moving Average | 790.40 |
| 200-Day Moving Average | 944.64 |
| Relative Strength Index (RSI) | 45.79 |
| Average Volume (20 Days) | 214,195 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Takara Bio had revenue of JPY 45.04 billion and earned 1.04 billion in profits. Earnings per share was 8.65.
| Revenue | 45.04B |
| Gross Profit | 26.07B |
| Operating Income | 2.26B |
| Pretax Income | 2.00B |
| Net Income | 1.04B |
| EBITDA | 6.74B |
| EBIT | 2.26B |
| Earnings Per Share (EPS) | 8.65 |
Balance Sheet
The company has 29.55 billion in cash and 1.10 billion in debt, giving a net cash position of 28.45 billion or 236.25 per share.
| Cash & Cash Equivalents | 29.55B |
| Total Debt | 1.10B |
| Net Cash | 28.45B |
| Net Cash Per Share | 236.25 |
| Equity (Book Value) | 115.85B |
| Book Value Per Share | 959.17 |
| Working Capital | 50.55B |
Cash Flow
In the last 12 months, operating cash flow was 5.84 billion and capital expenditures -9.87 billion, giving a free cash flow of -4.03 billion.
| Operating Cash Flow | 5.84B |
| Capital Expenditures | -9.87B |
| Free Cash Flow | -4.03B |
| FCF Per Share | -33.44 |
Margins
Gross margin is 57.88%, with operating and profit margins of 5.02% and 2.31%.
| Gross Margin | 57.88% |
| Operating Margin | 5.02% |
| Pretax Margin | 4.43% |
| Profit Margin | 2.31% |
| EBITDA Margin | 14.97% |
| EBIT Margin | 5.02% |
| FCF Margin | n/a |
Dividends & Yields
This stock pays an annual dividend of 17.00, which amounts to a dividend yield of 2.15%.
| Dividend Per Share | 17.00 |
| Dividend Yield | 2.15% |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | 196.73% |
| Buyback Yield | n/a |
| Shareholder Yield | 2.12% |
| Earnings Yield | 1.10% |
| FCF Yield | -4.27% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
The last stock split was on March 29, 2011. It was a forward split with a ratio of 400.
| Last Split Date | Mar 29, 2011 |
| Split Type | Forward |
| Split Ratio | 400 |
Scores
Takara Bio has an Altman Z-Score of 9.22 and a Piotroski F-Score of 5.
| Altman Z-Score | 9.22 |
| Piotroski F-Score | 5 |